NAD+ Oral Supplement Pilot Intervention in Adult Females
NAD+ Oral Supplement Pilot Intervention in Adult Females
NCT ID: NCT06579209 Phase: NA Status: COMPLETED Enrollment: 53 Completion: 2026-02-20
Conditions
Cognitive Change, Inflammation, Neurodegenerative Diseases
Interventions
Treatment, Placebo
Summary
The goal of this clinical trial is to learn whether Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women aged 40-80. The main questions it aims to answer are:
Will cognitive functioning change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving NAD+ to those receiving placebo to see if the results differ.
Participants will:
Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw
Primary Outcome
Neurocognition